Objective: To examine the expression of ATAD2 in different liver lesions and its clinical significance. Methods: ATAD2 expression in 60 hepatocellular carcinoma (HCC) surgical specimens (49 of which have concurrent liver cirrhosis), 43 HCC biopsy specimens, 2 high-grade liver dysplastic nodule specimens, 3 low-grade liver dysplastic nodule specimens, 50 liver cirrhosis tissue samples, and 20 normal liver tissue samples were measured using immunohistochemistry. The F-test, q-test, t-test, and chi-square test were used for statistical analysis of data. Results: ATAD2 was expressed in 56 HCC surgical specimens (93.33%), 35 HCC biopsy specimens (81.40%), and 2 high-grade liver dysplastic nodule specimens (2/2), but not in the low-grade liver dysplastic nodule, liver cirrhosis tissue, and normal liver tissue samples. The mean expression of ATAD2 was significantly higher in HCC tissues than in high-grade and low-grade liver dysplastic nodule tissues, liver cirrhosis tissue, and normal liver tissue (F = 22.96, q = 3.138, 3.972, 12.272, and 9.101, respectively, all P < 0.01). There were no significant differences in the mean expression and positive expression rate of ATAD2 between HCC surgical and biopsy specimens (t = 1.40, P > 0.05; χ² = 3.47, P >0.05). Of the 35 HCC biopsy specimens that expressed ATAD2, the mean ATAD2 expression was ≥1% in 35 specimens (100%), ≥3% in 27 specimens (77.14%), and ≥5 % in 23 specimens (65.71%). In addition, among the pathological grade I-II HCC biopsy specimens, the mean ATAD2 expression was ≥1% in 28 specimens (100%), ≥3% in 22 specimens (62.86%), and ≥5% in 19 specimens (54.29%). Moreover, ATAD2 expression in HCC was associated with serum alpha-fetoprotein level, presence of hepatitis B virus surface antigen (HBsAg), and presence of concurrent liver cirrhosis (t = 2.09, 2.30, and 2.18, respectively, all P < 0.05). Conclusion: ATAD2 may play an important role in HCC tumorigenesis, and may be involved in malignant transformation of cells. ATAD2 expression can be a valuable marker for differentiating the nature of lesions in liver biopsy tissues during clinical practice.
目的： 探讨三磷酸腺苷酶家族蛋白2（ATAD2）在不同病变肝组织中的表达情况及其临床应用价值。 方法： 用免疫组织化学法检测ATAD2在60例肝细胞肝癌手术标本（其中49例合并肝硬化）、43例肝细胞肝癌穿刺标本、2例肝脏高级别异型增生结节标本、3例肝脏低级别异型增生结节标本、50例肝硬化标本及20例相对正常肝组织标本中的表达情况。据资料不同分别采用F检验、q检验、t检验和χ(2)检验进行统计学分析。 结果： ATAD2在56例（93.33%）肝细胞肝癌手术标本中有表达，在35例（81.40%）肝细胞肝癌穿刺标本中有表达，在2例（2/2）肝脏高级别异型增生结节组织中有表达；在肝脏低级别异型增生结节、肝硬化及相对正常肝组织中均不表达。ATAD2在肝细胞肝癌中的平均表达量明显高于肝脏高级别异型增生结节、肝脏低级别异型增生结节、肝硬化及相对正常肝组织，差异均具有统计学意义（F = 22.96, q值分别为3.138、3.972、12.272、9.101，P值均< 0.01）。ATAD2在肝细胞肝癌手术标本及穿刺标本中的平均表达量及阳性表达率差异均无统计学意义（t = 1.40，P > 0.05；χ(2)= 3.47，P > 0.05）。35例表达ATAD2的肝细胞肝癌穿刺组织中有35例（100%）平均表达量≥1%，27例（77.14%）平均表达量≥3%，23例（65.71%）平均表达量≥5%。其中，在病理分级为Ⅰ～Ⅱ级的肝细胞肝癌穿刺组织中有28例（100%）平均表达量≥1%，22例（62.86%）平均表达量≥3%，19例（54.29%）平均表达量≥5%。此外，ATAD2在肝细胞肝癌中的表达水平与患者血清甲胎蛋白（AFP）水平、是否携带乙型肝炎表面抗原，以及是否合并肝硬化具有相关性（t值分别为2.09、2.30、2.18，P值均< 0.05）。 结论： ATAD2在肝细胞肝癌的发生中可能起重要作用，并参与了细胞的恶性转化，ATAD2的表达对判断临床肝穿刺组织的病变性质具有较高的参考价值。.
Keywords: ATAD2; Carcinoma, hepatocellular; Diagnosis; Tumorigenesis.